biostudies-literatureSmall DMPublic Health Agency24-31https://www.ebi.ac.uk/biostudies/studies/S-EPMC4426794biostudies-literatureUnknown23(1)Elafin is a serine protease inhibitor produced by epithelial and immune cells with anti-inflammatory properties. Research has shown that dysregulated protease activity may elicit proteolytic cleavage of elafin, thereby impairing the innate immune function of the protein. The aim of this study was to generate variants of elafin (GG- and QQ-elafin) that exhibit increased protease resistance while retaining the biological properties of wild-type (WT) elafin. Similar to WT-elafin, GG- and QQ-elafin variants retained antiprotease activity and susceptibility to transglutaminase-mediated fibronectin cross-linking. However, in contrast to WT-elafin, GG- and QQ-elafin displayed significantly enhanced resistance to degradation when incubated with bronchoalveolar lavage fluid from patients with cystiMolecular therapy : the journal of the American Society of Gene TherapyA functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.PMC4426794CDV/3778/08COM/4275/10Small DMQuinn DJWeldon SGlasgow AMZani MLDallet-Choisy SMcAuley DFTaggart CCMcNally PO'Kane CMoreau TfalseA functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.Elafin is a serine protease inhibitor produced by epithelial and immune cells with anti-inflammatory properties. Research has shown that dysregulated protease activity may elicit proteolytic cleavage of elafin, thereby impairing the innate immune function of the protein. The aim of this study was to generate variants of elafin (GG- and QQ-elafin) that exhibit increased protease resistance while retaining the biological properties of wild-type (WT) elafin. Similar to WT-elafin, GG- and QQ-elafin variants retained antiprotease activity and susceptibility to transglutaminase-mediated fibronectin cross-linking. However, in contrast to WT-elafin, GG- and QQ-elafin displayed significantly enhanced resistance to degradation when incubated with bronchoalveolar lavage fluid from patients with cysti2015-01-01T00:00:00Z2015 Jan2025-04-04T07:30:30.85Z2019-03-27T01:51:21ZS-EPMC44267942518974010.1038/mt.2014.162